On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet ...

After revealing in February plans to save $2 billion more on top of a previously disclosed cost-cutting initiative, Bristol ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...